Treatment Patterns of Atopic Dermatitis Medication in 0–10-Year-Olds: A Nationwide Prescription-Based Study
Open Access
- 28 June 2022
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 12 (7) , 1639-1657
Abstract
Introduction The literature on treatment patterns for paediatric atopic dermatitis (AD) is scarce and is rarely based on real-world data. Using national registers, we sought to establish up-to-date, population-based prevalence estimates, predictors of risk and disease burden and a comprehensive overview of treatment patterns and course for paediatric patients with AD. Methods Dispensed prescriptions for the entire Norwegian child population aged 0–10 years from 2014 to 2020 were analysed. Results There were 176,458 paediatric patients with AD. Of these, 99.2% received topical corticosteroids, 5.1% received topical calcineurin inhibitors, 37.1% received potent topical corticosteroids and 2.1% received systemic corticosteroids. Of the 59,335 live births in Norway (2014), 14,385 [24.8%; 95% confidence interval (CI) 24.5–25.1] paediatric patients were treated for AD before the age of 6 years, and of these, only 934 (6.5%; 95% CI 6.1–6.9) received medication annually for 5 years or more. Compared with girls, 17.9% (95% CI 6.5–27.9) more boys were treated for at least 5 years, receiving 6.4% (95% CI 1.2–11.3) more potent topical corticosteroids and 12.4% (95% CI 6.5–18.0) more were treated for skin infections. Compared with patients with late-onset treatment, 18.9% (95% CI 7.5–29.0) more paediatric patients with early-onset treatment were still receiving treatment at 5 years of age, 15.7% (95% CI 7.1–23.4) more paediatric patients received potent topical corticosteroids and 44.4% (95% CI 36.5–51.2) more paediatric patients were treated for skin infections. Conclusion Most paediatric patients were treated for a mild disease for a limited period. Although the prevalence of AD is higher at a younger age, these paediatric patients were the least likely to receive potent topical corticosteroids. Male sex and early-onset AD are associated with and are potential predictors of long-term treatment and treatment of potent topical corticosteroids, antihistamines and skin infections, which may have clinical utility for personalised prognosis, healthcare planning and future AD prevention trials.Keywords
Funding Information
- Sanofi Genzyme (E003730120)
- Norwegian Research Fund for General Practice (AMFF)
This publication has 49 references indexed in Scilit:
- Filaggrin loss-of-function mutations are not associated with atopic dermatitis that develops in late childhood or adulthoodBritish Journal of Dermatology, 2015
- Complementary and Alternative Medicines and Childhood Eczema: A US Population-Based StudyDermatitis®, 2014
- The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin ConditionsJournal of Investigative Dermatology, 2014
- Associations of Childhood Eczema Severity: A US Population-Based StudyDermatitis®, 2014
- Validation of asthma and eczema in population‐based Swedish drug and patient registersPharmacoepidemiology and Drug Safety, 2013
- Adherence to topical therapy increases around the time of office visitsJournal of the American Academy of Dermatology, 2007
- Gender-specific presentations for asthma, allergic rhinitis and eczema in primary carePrimary Care Respiratory Journal, 2007
- Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitisJournal of the American Academy of Dermatology, 2007
- Differential effects of risk factors on infant wheeze and atopic dermatitis emphasize a different etiologyJournal of Allergy and Clinical Immunology, 2006
- Cyclosporin in atopic dermatitis: a multicentre placebo-controlled studyBritish Journal of Dermatology, 1994